Roche
ROG
Performance
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science toimprove people's lives. The combined strengths of pharmaceuticals and diagnostics under one roofhave made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treatdiseases and make a sustainable contribution to society. The company also aims for improvingpatient access to medical innovations by working with all relevant stakeholders. Twenty-ninemedicines developed by Roche are included in the World Health Organization Model Lists ofEssential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals,Biotechnology; Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&Dand posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned memberof the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information: or
Recent News
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
5 FDA Decisions to Watch in the First Quarter of 2026
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
Biotech in 2025: A Retrospective
Roche Secures CE Mark for Elecsys NfL Blood Test to Track MS Neuroinflammation
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial
Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
Salesforce vs Veeva - the Game's Afoot and the Life Sciences Battleground Is Hotting Up!
AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation
GSK Moves Ovarian Cancer ADC Mo-Rez Into Five Phase 3 Trials
Deep Dive: Huntington’s at a Crossroads
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Gepotidacin
Boehringer Drug Scores in Rare Kidney Disease FSGS
Up the Ranks: Nokia Welcomes Kristen Pressner as Chief People Officer
Why Owning the Learning Loop Matters More Than Owning the Lab
Proteasomes: A Novel Approach to Target the Immune System
Discovery-Driven Planning: A Better Way to Evaluate Venture Investments
Doctolib, AP-HP, and Roche Launch Startup Programme to Bridge Healthtech–Clinical Gap
CMS's Medicare Price Negotiations Start Round Three
Devyser Partners with Illumina
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
Nine Biotech Companies that Could Revolutionize Obesity Treatments
New HPV Test Kit for At-Home Use Secures FDA Clearance
Roche’s DAC Investment; Big Pharma’s Lavish CEO Bumps
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Could Alzheimer's Be Predicted with a Finger-Prick Test?
Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals
FDA Receives sBLA for Zenocutuzumab Targeting NRG1‑Positive Cholangiocarcinoma
Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes
IDEAYA Biosciences Shows 58% Reduction in Disease Progression in Late‑Stage Uveal Melanoma Trial
#ACTRIMS26: Roche’s MS Drug Fenebrutinib Beats Ocrevus, Cutting Risk of Disability Progression by 12%
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
What Happened in Tech While You Weren’t Looking
The New Gold Rush in Brain Science
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
Roche’s Obesity Shot Posts Decent Weight Loss in Mid-Stage Test, Heads to Phase 3
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
Parkinson’s Awareness Month and World Parkinson’s Day 2026: Advocacy and Therapeutic Progress
Fenebrutinib (GDC-0853)
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
Ollin’s Drug Clears Retinal Disease Better than Roche’s Vabysmo in Phase 1b Trial
Evolution of the European HealthTech and MedTech Advisory Ecosystem: Rise of Founder Bankers and Specialist Boutiques